Free Trial

Intellia Therapeutics (NTLA) Competitors

Intellia Therapeutics logo
$12.06 +0.23 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$12.04 -0.02 (-0.12%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NTLA vs. BEAM, CRSP, EDIT, PCVX, CYTK, MTSR, ADMA, KRYS, AKRO, and RNA

Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

Intellia Therapeutics vs. Its Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$57.88M21.58-$519.02M-$5.23-2.31
Beam Therapeutics$63.52M32.85-$376.74M-$4.61-4.50

Beam Therapeutics has a net margin of -609.24% compared to Intellia Therapeutics' net margin of -1,154.10%. Beam Therapeutics' return on equity of -44.24% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-1,154.10% -56.06% -44.25%
Beam Therapeutics -609.24%-44.24%-30.97%

Intellia Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Intellia Therapeutics presently has a consensus price target of $33.37, suggesting a potential upside of 176.69%. Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 134.94%. Given Intellia Therapeutics' higher probable upside, research analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Beam Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.48 beat Beam Therapeutics' score of 0.47 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Beam Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTLA vs. The Competition

MetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.23B$2.96B$5.54B$9.41B
Dividend YieldN/A2.47%3.75%4.03%
P/E Ratio-2.3119.7528.0119.82
Price / Sales21.58299.50432.7298.44
Price / CashN/A42.5936.1658.27
Price / Book1.417.678.125.65
Net Income-$519.02M-$55.28M$3.25B$257.91M
7 Day Performance4.60%2.50%0.97%2.09%
1 Month Performance25.63%11.70%7.36%11.13%
1 Year Performance-53.78%4.89%31.31%18.40%

Intellia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTLA
Intellia Therapeutics
4.4072 of 5 stars
$12.06
+1.9%
$33.37
+176.7%
-56.8%$1.23B$57.88M-2.31600Gap Up
BEAM
Beam Therapeutics
2.0658 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-24.1%$2.13B$63.52M-4.59510Gap Up
CRSP
CRISPR Therapeutics
2.69 of 5 stars
$56.42
-0.7%
$71.75
+27.2%
-8.9%$4.87B$37.31M-12.48460Insider Trade
Analyst Revision
Gap Up
EDIT
Editas Medicine
4.0918 of 5 stars
$2.85
-1.0%
$4.70
+64.9%
-52.3%$238.57M$32.31M-0.94230News Coverage
Positive News
PCVX
Vaxcyte
1.801 of 5 stars
$36.38
+1.3%
$136.50
+275.2%
-54.1%$4.69BN/A-9.12160Positive News
CYTK
Cytokinetics
4.0425 of 5 stars
$38.58
+4.2%
$70.92
+83.8%
-31.5%$4.61B$18.47M-7.29250Insider Trade
MTSR
Metsera
N/A$42.47
+8.1%
$55.00
+29.5%
N/A$4.46BN/A0.0081
ADMA
ADMA Biologics
3.8794 of 5 stars
$18.68
+0.9%
$27.67
+48.1%
+32.4%$4.46B$426.45M21.98530Positive News
KRYS
Krystal Biotech
4.5474 of 5 stars
$150.41
+1.5%
$213.75
+42.1%
-27.6%$4.35B$290.52M36.16210Insider Trade
Analyst Revision
AKRO
Akero Therapeutics
3.6777 of 5 stars
$52.73
+2.2%
$82.50
+56.5%
+100.6%$4.20BN/A-27.0430Positive News
Insider Trade
RNA
Avidity Biosciences
2.1866 of 5 stars
$33.57
+6.7%
$66.35
+97.7%
-24.6%$4.05B$8.93M-11.19190High Trading Volume

Related Companies and Tools


This page (NASDAQ:NTLA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners